FDA Approves Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease

Article Link: FDA Approves Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease

November 25, 2019 — Today, the U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
“Today’s…

Source: FDA New Drug Approvals